Tecan to present at upcoming Investor Conferences

06.01.25 13:30 Uhr

Werte in diesem Artikel
Aktien

214,20 CHF 7,20 CHF 3,48%

Männedorf, Switzerland, January 6, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences in the upcoming weeks:

Wer­bung

Baader Helvea Swiss Equities Conference, Bad Ragaz, Switzerland
Date: 9 January 2025
Participants: Dr. Achim von Leoprechting, CEO
        Tania Micki, CFO
        Martin Brändle, SVP, Corp. Comm. & Investor Relations
Not webcasted.

Octavian Seminar 2025, Davos, Switzerland
Date: 10 January 2025
Participants: Dr. Achim von Leoprechting, CEO
        Tania Micki, CFO
        Martin Brändle, SVP, Corp. Comm. & Investor Relations
Not webcasted.

Wer­bung

43rd Annual J.P. Morgan Healthcare Conference, San Francisco, USA
Date: 15 January 2025
Presentation: 09:00am PST (6:00pm CET)
Presenter: Dr. Achim von Leoprechting, CEO, Tecan
Additional participants: Tania Micki, CFO & Martin Brändle, SVP, Corp. Comm. & Investor Relations
Webcast live under the "Investor Relations" tab of Tecan's website www.tecan.com.
A replay of the webcast will be available after the presentation and will remain available for 30 days.

About Tecan
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,500 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2023, Tecan generated sales of CHF 1,074 million (USD 1,194 million; EUR 1,108 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
        
        
For further information:

Wer­bung

Tecan Group
Martin Braendle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Attachment


Ausgewählte Hebelprodukte auf Tecan (N)

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Tecan (N)

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Tecan (N)

Wer­bung

Analysen zu Tecan (N)

DatumRatingAnalyst
28.02.2013Tecan Group (N) haltenVontobel Research
30.01.2013Tecan Group (N) haltenVontobel Research
11.12.2012Tecan Group (N) buyUBS AG
02.10.2012Tecan Group (N) neutralSarasin Research
17.08.2012Tecan Group (N) holdVontobel Research
DatumRatingAnalyst
11.12.2012Tecan Group (N) buyUBS AG
17.08.2012Tecan Group (N) buyUBS AG
19.08.2011Tecan Group (N) buyVontobel Research
18.08.2011Tecan Group (N) buyVontobel Research
25.07.2011Tecan Group (N) buyVontobel Research
DatumRatingAnalyst
28.02.2013Tecan Group (N) haltenVontobel Research
30.01.2013Tecan Group (N) haltenVontobel Research
02.10.2012Tecan Group (N) neutralSarasin Research
17.08.2012Tecan Group (N) holdVontobel Research
16.08.2012Tecan Group (N) holdVontobel Research
DatumRatingAnalyst
17.03.2005Tecan: ReduceHelvea
19.01.2005Tecan: ReduceHelvea

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Tecan (N) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"